Clinical Focus

  • Hospice and Palliative Medicine
  • Clinics, Outpatient
  • Hospice Care

Academic Appointments

Administrative Appointments

  • Associate medical director, VITAS Healthcare (2013 - Present)

Honors & Awards

  • VITAS BEST Award, VITAS Healtchare (2014)
  • VITAS Leadership Council Award for Outstanding Team Physician, VITAS Healthcare (2012)
  • Member, Alpha Omega Alpha Medical Honor Society (2006-present)

Boards, Advisory Committees, Professional Organizations

  • Member, ABIM SEP Committee for Hospice and Palliative Medicine (2014 - Present)
  • Co-chair, VITAS Healthcare San Francisco Bay Program Ethics Committee (2012 - Present)

Professional Education

  • Board Certification: Hospice and Palliative Medicine, American Board of Internal Medicine (2010)
  • Board Certification: Internal Medicine, American Board of Internal Medicine (2009)
  • Fellowship:VA Medical Center Palo Alto (2010) CA
  • Residency:Stanford University Hospital -Clinical Excellence Research Center (2009) CA
  • Internship:Stanford University Hospital -Clinical Excellence Research Center (2007) CA
  • Medical Education:Oregon Health Science University (2006) OR


Graduate and Fellowship Programs

  • Hospice & Palliative Medicine (Fellowship Program)


All Publications

  • Malignancy in the Setting of the Anti-Synthetase Syndrome JCR-JOURNAL OF CLINICAL RHEUMATOLOGY Rozelle, A., Trieu, S., Chung, L. 2008; 14 (5): 285-288


    Malignancy and interstitial lung disease (ILD) are 2 conditions associated with dermatomyositis (DM) that are responsible for a significant portion of the morbidity and mortality related to this disease; however, they rarely occur in the same patient. The antisynthetase syndrome consists of several characteristics, including ILD, arthritis, Raynaud phenomenon, "mechanic's hands," and positive antibodies to tRNA synthetases, which have each been negatively associated with cancer. When patients with DM present with such characteristics, clinicians may be falsely reassured that a thorough malignancy screen is unnecessary. We describe a patient who presented with the antisynthetase syndrome and was subsequently found to have colon cancer. Removal of the cancer led to resolution of the myositis and lung disease, but the patient's rash and arthritis persisted and ultimately required immunosuppressive therapy. We provide a review of the literature describing the concurrence of both this syndrome and ILD alone, with malignancy. We conclude that a thorough and expedited age-appropriate malignancy work up is indicated in all patients with a new diagnosis of DM, despite the presence of disease characteristics that are usually not associated with cancer.

    View details for DOI 10.1097/RHU.0b013e31817d116f

    View details for Web of Science ID 000260154000008

    View details for PubMedID 18664993

Footer Links:

Stanford Medicine Resources: